Inclusion Criteria:  Subject is aged 18-75 years at time of screening Subject is on MDI therapy (defined as ≥ 3 insulin injections per day and on a basal/bolus regimen) ≥1 year prior to screening Subject has a clinical diagnosis of type 1 diabetes for 1 year prior to screening Subject has a Glycosylated hemoglobin (HbA1c) less than 10% as assessed by local lab <15 days prior to screening or at time of screening visit  Subject is on MDI therapy with  SMBG, Continuous Glucose Monitoring (CGM), or Intermittent Scanning CGM (iscCGM) Subject is willing to upload data from a BG meter, must have internet access and a compatible computer system that meets the requirements for uploading data at home. Subject is willing and able to sign and date informed consent, comply with all study procedures, and wear all study devices, as required during the study.  Subject is willing to take or switch to one of the following insulins:  Humalog™* (insulin lispro injection) NovoLog™* (insulin aspart)  Exclusion Criteria:  Women of child-bearing potential who have a positive pregnancy test at screening or plan to become pregnant during the course of the study. Women who are breastfeeding. Subject has any unresolved adverse skin conditions in the area of sensor placement (e.g. psoriasis, dermatitis herpetiformis, rash, Staphylococcus infection). Subject is actively participating in an investigational study (drug or device) wherein he/she has received treatment from an investigational study drug or device in the last 2 weeks before enrollment into this study, as per investigator judgment. Subject is currently abusing illicit drugs, marijuana, alcohol or prescription drugs (other than nicotine), per investigator judgment. Subject has any other disease or condition that may preclude the patient from participating in the study, per investigator judgment. Subject is legally incompetent, illiterate or vulnerable person. Research staff involved with executing the study.